Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis study shows “long-term safety” of Lantus

Sanofi-Aventis study shows “long-term safety” of Lantus

6th July 2009

Sanofi-Aventis has published the findings from a new study, which it says is demonstrative of the “long-term safety” of Lantus (insultin glagine [rDNA] injection).

The research was undertaken over a period of five years and was published online in the industry publication Diabetologia.

It examined the effects of Lantus against NPH insulin on progression of retinopathy in participants with type 2 diabetes and showed similar effects in both of the two test groups, as well as the overall safety of both treatments, the company said.

Lead investigator Julio Rosenstock said that the trial, which involved 1,024 patients, represented the longest randomised, controlled study with insulin glargine tested against NPH human insulin.

Retiontherapy progression was assessed in the participants using serial fundus photography and evaluated using the Early Treatment Diabetic Retinotherapy Scale.

Mr Rosenstock added: “This study demonstrated no evidence of a greater risk of progression of retinotherapy with insulin glargine.”

In recent days, Sanofi-Aventis presented a new research and development model that it said aims to increase innovation.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.